Frontier Science Foundation-Hellas
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
2011 · Luca Gianni, Urania Dafni, et al. · The Lancet Oncology
ESMO-Magnitude of Clinical Benefit Scale version 1.1
2017 · Nathan I. Cherny, Urania Dafni, et al. · Annals of Oncology
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
2022 · Mary O’Brien, Luís Paz-Ares, et al. · The Lancet Oncology